Medindia

X

Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMed's Peer-Reviewed Video Journal JoVE

Thursday, September 18, 2008 General News J E 4
Advertisement
ST. LOUIS, Sept. 17 Sigma-Aldrich (Nasdaq: SIAL)today announced the publication of its first peer-reviewed video protocol inthe PubMed accessible Journal of Visualized Experiments (JoVE). This makesSigma-Aldrich the first life science company to submit a video protocol to thetraditional scientific publication process. Peer-reviewed video protocols arean innovative and highly effective tool to increase the efficiency ofscientific communication and with it the speed of basic research and drugdiscovery (http://www.jove.com/index/Details.stp?ID=899).

"Producing peer reviewed resources and making them available in locationsthat researchers trust is an invaluable tool for the research community," saidJohn Custer, Marketing Manager-Biochemistry for Sigma-Aldrich. "We lookforward to hearing our customers' feedback while we continue working onadditional video protocols."

Less than two years old, JoVE is a scientific journal that publishes videoarticles of biological experiments from leading academic institutionsincluding Harvard, MIT, Stanford, and Berkeley. JoVE recently became the firstand only video-based scientific journal to be indexed in MEDLINE and PubMed,the official repositories of the National Library of Medicine (NLM) at theNational Institute of Health (NIH).

"Scientists depend on fast access to high quality information both fromother scientists and increasingly from industry. The fact that an industryleader dedicates its resources to make its scientific knowledge accessibleusing the most innovative forms of scientific communication will stronglybenefit the scientific community," said Klaus Korak, co-founder of JoVE.

The first video protocol titled, Sigma's Non-Specific Protease ActivityAssay -- Casein as a Substrate, is a multipurpose protease assay employed bylife science researchers in academia, biotech, and pharmaceutical industry.The video protocol can be viewed on JoVE and the Sigma Aldrich website and isavailable in both English and Chinese. Sigma Aldrich plans to continuecreating video protocols spanning many different topics of scientificresearch.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and HighTechnology company. Our biochemical and organic chemical products and kits areused in scientific and genomic research, biotechnology, pharmaceuticaldevelopment, the diagnosis of disease and as key components in pharmaceuticaland other high technology manufacturing. We have customers in life sciencecompanies, university and government institutions, hospitals, and in industry.Over one million scientists and technologists use our products. Sigma-Aldrichoperates in 36 countries and has 8,000 employees providing excellent serviceworldwide. Sigma-Aldrich is committed to Accelerating Customer Success throughLeadership in Life Science, High Technology and Service. For more informationabout Sigma-Aldrich, please visit our award-winning website athttp://www.sigma-aldrich.com.

About JoVE: JoVE is the first-and-only video-based scientific journalindexed in MEDLINE and PubMed. JoVE was founded in October 2006 as the firstonline journal devoted to video-publication of life science research. Thisnovel, dynamic, and visual approach to scientific publishing aims to increasethe reproducibility of published studies and to improve the efficiency ofresearch in the biological sciences. JoVE has assembled an Editorial Boardthat includes 24 scientists from Harvard, Princeton, NIH, and other leadinginstitutions across the US, Europe, and Japan. JoVE has so far released 19monthly issues including over 230 video protocols on experimental approachesin developmental biology, neuroscience, microbiology and other fields. Tofacilitate the integration of video content into scientific publishing, JoVEhas developed an organizational and technical infrastructure to perform and/orassist scientists with filming and editing in their
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Oncothyreon announces receipt of NASDAQ letter reg...
S
Plexus Systems, Inc. to Exhibit at AdvaMed 2008 Me...